MS Drug Tysabri (Natalizumab) Poses Hard Choices for Women Wanting Children

THURSDAY, Feb. 8, 2018 -- A powerful multiple sclerosis drug presents women with a tough dilemma if they would like to have children, a pair of new studies suggests. Those who take Tysabri (natalizumab) to manage their MS are more likely to suffer...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

Xia Jiang, Tomas Olsson, Lars Alfredsson
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractThe past decade has seen extraordinary increase in worldwide availability of and access to several large multiple sclerosis (MS) databases and registries. MS registries represent powerful tools to provide meaningful information on the burden, natural history, and long-term safety and effectiveness of treatments. Moreover, patients, physicians, industry, and policy makers have an active interest in real-world observational studies based on register data, as they have the potential to answer the questions that are most relevant to daily treatment decision-making. In 2014, the Italian MS Foundation, in collaboration w...
Source: Neurological Sciences - Category: Neurology Source Type: research
(Karolinska Institutet) Mapping of a certain group of cells, known as oligodendrocytes, in the central nervous system of a mouse model of multiple sclerosis (MS), shows that they might have a significant role in the development of the disease. The discovery can lead to new therapies targeted at other areas than just the immune system. The results are published in Nature Medicine by researchers at Karolinska Institutet in Sweden.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
In this study, we compared the incidence and characteristics of acute epileptic seizures in MOG-EM and NMOSD patients.MethodsMOG-EM (n=61) and NMOSD (n=565) cases obtained from the MSNMOBase (2011–2018) were retrospectively reviewed.ResultsAcute epileptic seizures were observed in 13 (21.3%) patients with MOG-EM and two (0.4%) patients with NMOSD (P
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 10 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Duygu Kocyigit, Muhammed U Yalcin, Kadri M Gurses, Lale Tokgozoglu, Rana KarabudakAbstractBACKGROUNDFingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, is used for treatment of relapsing-remitting multiple sclerosis (RRMS). S1P receptors that fingolimod acts upon have also been shown to be expressed on atrial myocytes. This expression pattern has been linked with the drug's cardiovascular effects, such as bradycardia. We aimed to evaluate the clinical and electrocardiographic predictors of heart rate (HR)...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Conclusion: Approximately 1 in 10 individuals discontinued their first oral DMT within 6 months, and 1 in 5 did so within one year. However, among those who did continue drug, a high proportion (>80%) exhibited optimal adherence. Predictors of persistence or adherence with immediate practical application were lacking; this highlights the challenges in optimizing drug therapy.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 9 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Tom A. Fuchs, Caila B. Vaughn, Ralph H.B. Benedict, Bianca Weinstock-Guttman, Sanjeevani Choudhery, Keith Carolus, Patrick Rooney, Kira Ashton, Deepa Ramasamy, Dejan Jakimovski, Robert Zivadinov, Michael G. DwyerAbstractBackgroundFatigue, a frequent and disabling symptom for people with multiple sclerosis (PwMS), inconsistently correlates with white matter (WM) pathology. Network-based analysis, accounting for the manner in which lesions disrupt networks of structurally connected gray matter (GM) regions, may provid...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
In conclusion, Bacoside-A can able to inhibit the progression of EAE may be by the inhibition of inflammatory cytokines and chemokine evolved during active EAE.Graphical abstract
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 10 November 2018Source: Journal of NeuroradiologyAuthor(s): Clarisse Carra-Dalliere, Nicolas Menjot de Champfleur, Xavier Ayrignac, Pierre Labauge
Source: Journal of Neuroradiology - Category: Radiology Source Type: research
This study aimed to assess STAT1, STAT2 and STAT3 gene expression in the blood of 50 relapsing-remitting MS (RR-MS) patients and 50 healthy controls by TaqMan Quantitative Real-Time PCR. RESULTS: The results showed that STAT1 gene expression was significantly up-regulated (p= 0.023), whereas STAT2 gene expression was significantly down-regulated (p
Source: Human Antibodies - Category: Biochemistry Tags: Hum Antibodies Source Type: research
More News: Children | General Medicine | Multiple Sclerosis | Study | Tysabri | Women